Follow the
footnotes.
Each public record has its own access date. Original publication dates and evidence limits still matter.
- 01Manufacturer product page
CoreAge Rx — GLP-1 Support ↗
Public offer, species and prebiotic ingredient statements. Complete current panel, strain identifiers and viable-organism amount were not established. Commercial source; no independent product test.
Accessed 2026-09-27 - 02Manufacturer image
CoreAge Rx — public front-bottle image ↗
Front image shows 30 capsules and a 36 mg blend statement. This is not a complete Supplement Facts panel or a CFU/AFU declaration.
Accessed 2026-09-26 - 03Manufacturer product page
Pendulum — GLP-1 Probiotic ↗
Rendered public offers and consumer-survey qualification checked. Purchase, fulfillment, cancellation and reimbursement were not tested. Survey and preclinical statements are not established clinical outcomes for medication users.
Accessed 2026-09-26 - 04Manufacturer label image
Pendulum — GLP-1 Probiotic facts image ↗
Visually inspected: 500 million AFU blend, two named strain codes, B. infantis without code, 211 mg chicory inulin, 30 one-capsule servings. Does not establish a per-strain amount or CFU equivalence.
Accessed 2026-09-26 - 05Manufacturer research summary
Pendulum — GLP-1 science page ↗
Preclinical qualification and 274-person consumer-study description. Not independently controlled evidence of a retail-product weight-loss or prescription-tolerability outcome.
Accessed 2026-09-26 - 06Sponsor research directory
Pendulum — clinical-trials directory ↗
The two-phase healthy-adult entry still lists estimated 2025 completion and active/fully enrolled wording. Current status and completed findings were not independently established. Other formulas are distinct.
Accessed 2026-09-26 - 07Manufacturer product page
Align — standard 24/7 Digestive Support ↗
US standard capsule, different count options, incentivized-rating disclosure. Retailer price unverified. Do not transfer to gummies or other Align variants.
Accessed 2026-09-26 - 08Manufacturer-linked label image
Align — 28-serving facts image ↗
Visually inspected B. longum subsp. longum 35624, 10 mg, one billion CFU at manufacture and ten million cells through best-by. Image describes 28 servings, not all retail counts.
Accessed 2026-09-26 - 09Manufacturer guidance
Align — how to take and store the standard capsule ↗
Manufacturer count-date and storage statements. Descriptions of effectiveness or timing are commercial claims, not personal advice.
Accessed 2026-09-26 - 10Primary trial abstract
Whorwell et al. — 35624 trial in women with IBS, 2006 ↗
362 women; four-week intervention and three tested amounts. Only the middle amount significantly separated; highest had formulation problems. Abstract read; not a GLP-1-medication trial or a personal regimen.
Accessed 2026-09-26 - 11Primary trial abstract
Ringel-Kulka et al. — 35624 in a non-patient population, 2017 ↗
302 randomized, 275 evaluable, four-week intervention. Mean symptom-severity differences were not significant; bloating-free days favored probiotic. Industry affiliation reported. Abstract-only appraisal.
Accessed 2026-09-26 - 12Primary research abstract
Altmann et al. — genome analysis of strain 35624, 2016 ↗
Genome-based assignment to B. longum subsp. longum explains older infantis naming for 35624. Mechanistic/taxonomic work; not a GLP-1 clinical outcome.
Accessed 2026-09-26 - 13Manufacturer product page
Florastor — standard adult Dual Action ↗
US adult standard formula and rendered package prices checked. Different Florastor products are separate. Checkout, delivery and returns untested.
Accessed 2026-09-26 - 14Manufacturer guidance
Florastor — product, storage and precaution FAQs ↗
250 mg per capsule, lactose and non-vegan disclosure, no refrigeration, and explicit exclusions for central lines/ports, ICU, severe immune compromise and other settings. No universal allergy or interaction clearance.
Accessed 2026-09-26 - 15Federal evidence fact sheet
NIH Office of Dietary Supplements — Probiotics ↗
Strain-specific evidence, label counts, shelf-life and safety context. General review; not endorsement or testing of the retail products.
Accessed 2026-09-27 - 16Federal health resource
NCCIH — Probiotics: Usefulness and Safety ↗
Evidence limitations and greater potential risk in severe illness or compromised immunity. Access date does not update the underlying studies.
Accessed 2026-09-27 - 17Federal consumer resource
FDA — consumer information about dietary supplements ↗
Supplement regulation and consumer precautions. Does not establish the safety or effectiveness of a particular product.
Accessed 2026-09-26 - 18Federal medicine information
MedlinePlus — semaglutide injection ↗
Prescription uses, precautions and adverse-effect information. Does not support treating medication-related symptoms with a probiotic.
Accessed 2026-09-27 - 19Federal medicine information
MedlinePlus — tirzepatide injection ↗
Prescription information and symptoms needing medical attention. No supplement regimen is derived from this page.
Accessed 2026-09-26 - 20Primary laboratory methods study
Visciglia et al. — probiotic enumeration and shelf-life methods, 2022 ↗
Flow cytometry and plate-count methods applied to a separate pediatric-targeted synbiotic. Authors report industry roles. Used for measurement context, not a clinical claim or validation of these products.
Accessed 2026-09-26 - 21Manufacturer product page
Visbiome — GI Care capsules ↗
Standard U.S. 60-capsule bottle with 112.5 billion CFU per capsule. Regular $69.95 price and a separate $62.95 recommendation-discount display; eligibility and checkout unverified. Medical-food, milk and cold-shipping statements are manufacturer records.
Accessed 2026-09-27 - 22Visually inspected manufacturer PDF
Visbiome — June 2026 linked package insert ↗
12-page insert; pages 1,2,5,9,10 inspected for category, warnings, strain list, AAD summary and storage. Contains milk. Lactose threshold wording differs from product-page trace statement; supplied batch not verified. Historical formulation and current products distinguished; no personal regimen.
Accessed 2026-09-27 - 23Manufacturer public product data
Visbiome — public product variant record ↗
Default variant regular price $69.95. Does not establish recommendation-discount eligibility, delivered stock, subscription commitment or checkout total.
Accessed 2026-09-27 - 24Primary randomized-trial abstract
Selinger et al. — historical probiotic formulation and antibiotic-associated diarrhea, 2013 ↗
229 hospitalized adults; historical VSL#3 formulation in sachets. Per-protocol AAD result significant; intention-to-treat result 4.3% versus 8.9%, P=0.19, not significant. No CDAD cases. Abstract-only appraisal; no GLP-1 outcome or direct current-capsule regimen claim.
Accessed 2026-09-27 - 25Professional guideline
AGA — probiotic guideline, June 2020 ↗
Specified-preparation prevention suggestion differs from ACG 2021. Symptomatic IBS use limited to clinical trials; not a universal retail endorsement. Read with newer population-specific guidance.
Accessed 2026-09-27 - 26Professional guideline
ACG — C. difficile guideline, 2021 ↗
Recommends against probiotic primary prevention during antibiotics and recurrence prevention. Distinct from antibiotic-associated diarrhea as a broader outcome.
Accessed 2026-09-27 - 27Clinical practice update
AGA — C. difficile infection in IBD, May 2026 ↗
Published May 15, 2026. Advises against probiotics for primary or secondary CDI prevention in IBD. Population-specific guidance; no prescription treatment instructions reproduced.
Accessed 2026-09-27 - 28Professional patient education
AGA patient center — probiotics ↗
Strain- and combination-specific context; general education is not proof for every mixture or GLP-1 user.
Accessed 2026-09-27 - 29Federal health guidance
CDC — C. difficile overview ↗
Contact a healthcare professional for diarrhea during or after antibiotics. Not every case is CDI; symptom assessment and testing are clinical decisions.
Accessed 2026-09-27 - 30Federal regulatory explanation
FDA — Is it really FDA approved? ↗
Medical foods are not preapproved like drugs; physician-supervision context. Does not adjudicate any reviewed brand's classification or certify safety.
Accessed 2026-09-27
